We recently published 11 Stocks on Jim Cramer’s Radar.  Chevron Corporation (NYSE:CVX) is one of the stocks on Jim Cramer radar. Oil giant Chevron Corporation (NYSE:CVX)’s shares witnessed considerable traction after the US action in Venezuela. On January 6th, Freedom Capital downgraded the shares to Sell from Hold as it commented that while oil prices were falling, the shares of oil companies were rising to create a dangerous trend. The financial firm added that Chevron Corporation (NYSE:CVX)’s shares, a ...

Group 1 - Kingdom Capital Advisors achieved a 17.45% return net of fees in 2025, despite facing significant challenges including a bankruptcy and a cyberattack [1] - The composite return for the fourth quarter was 8.88% net of fees, outperforming the Russell 2000 TR (2.19%), S&P 500 TR (2.68%), and NASDAQ 100 TR (2.47%) [1] - The firm focuses on investing in overlooked microcap companies to yield exceptional returns [1] Group 2 - Apartment Investment and Management Company (NYSE:AIV) had a one-month return of 1.64% but lost 34.17% of its value over the last 52 weeks, closing at $5.93 per share with a market capitalization of $847.885 million on January 8, 2026 [2] - AIV is in the process of selling properties and moving toward full liquidation, having sold the majority of their remaining stabilized apartments [3] - Kingdom Capital Advisors expects dividends in FY26 to cover their cost basis on AIV, anticipating substantial capital returns to shareholders as property sales finalize [3] Group 3 - AIV is not among the 30 Most Popular Stocks Among Hedge Funds, with 35 hedge fund portfolios holding AIV at the end of Q3, up from 26 in the previous quarter [4] - While AIV has potential as an investment, certain AI stocks are believed to offer greater upside potential and less downside risk [4]

Group 1: Kingdom Capital Advisors Performance - Kingdom Capital Advisors achieved a 17.45% return net of fees in 2025, despite facing significant challenges including a bankruptcy and a cyberattack [1] - The composite return for the fourth quarter was 8.88% net of fees, outperforming the Russell 2000 TR (2.19%), S&P 500 TR (2.68%), and NASDAQ 100 TR (2.47%) [1] Group 2: WW International, Inc. (NASDAQ:WW) Overview - WW International, Inc. (NASDAQ:WW) experienced a one-month return of 35.07% and a year-to-date gain of 17.85% over the past three months, with a market capitalization of $343.85 million as of January 8, 2026 [2] - Both WW International, Inc. and Magnera (MAGN) contributed positively to the fourth quarter returns, despite being year-to-date detractors [3] Group 3: Hedge Fund Interest and Investment Outlook - WW International, Inc. is held by 18 hedge fund portfolios at the end of the third quarter, but it is not among the 30 most popular stocks among hedge funds [4] - The company is acknowledged for its investment potential, but certain AI stocks are considered to offer greater upside potential and less downside risk [4]

Core Insights - Kingdom Capital Advisors achieved a 17.45% return net of fees in 2025, despite facing significant challenges including a bankruptcy and a cyberattack [1] - The firm's composite return for Q4 2025 was 8.88%, outperforming the Russell 2000 TR (2.19%), S&P 500 TR (2.68%), and NASDAQ 100 TR (2.47%) [1] Company Performance - United Natural Foods, Inc. (NYSE:UNFI) had a one-month return of 0.58% and a 52-week gain of 20.92%, closing at $33.00 per share with a market capitalization of $2.011 billion on January 8, 2026 [2] - Despite being a top contributor for FY25, UNFI faced challenges in Q4, with weakening investor sentiment impacting its stock performance [3] Market Position - UNFI was held by 25 hedge fund portfolios at the end of Q3 2025, a decrease from 27 in the previous quarter, indicating a slight decline in popularity among hedge funds [4] - The company's net sales for Q1 FY26 were $7.8 billion, consistent with the previous quarter, suggesting stable revenue performance [4]

Kingdom Capital Advisors, a private investment firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The firm started the business four years ago with a clear goal of investing in overlooked microcap companies that yield exceptional returns. Despite significant challenges in 2025, including a bankruptcy in January, a key investment losing customers in May, and a cyberattack on the largest holding in June, the firm achieved a 17.45% return net of fees, illustra ...

Company Overview - SI-BONE, Inc. (NASDAQ:SIBN) develops and sells medical devices targeting musculoskeletal disorders in the sacropelvic area, including minimally invasive implants for sacroiliac joint dysfunction, pelvic trauma, and spinal support [2]. Investment Sentiment - The company has been highlighted as a speculative investment opportunity, with notable interest from investment commentators, indicating a growing recognition in the market [1]. - There is a suggestion that while SI-BONE has potential, certain AI stocks may offer greater upside potential and carry less downside risk, indicating a competitive investment landscape [3].

Core Viewpoint - Alvotech (NASDAQ:ALVO) is positioned for a potential rebound, supported by a recent $100 million senior term loan facility aimed at enhancing liquidity and strategic execution through 2026 [1][3]. Financing and Investment - Alvotech has secured a $100 million senior term loan facility that will mature in December 2027, which will bolster the company's liquidity [1]. - The financing is led by GoldenTree Asset Management, indicating investor confidence in Alvotech's execution capabilities and the commercial potential of its biosimilar product pipeline [2]. Product Development and Strategy - Alvotech is advancing its research and development efforts with 30 biosimilar products currently in development [2]. - The company plans to expand its production capacity and enhance its supply chain to support four new global product launches scheduled through 2026 [2]. Market Sentiment and Industry Outlook - Barclays initiated coverage on Alvotech with an Underweight rating and a price target of $5, reflecting a cautious outlook despite improving investor sentiment in the specialty pharmaceuticals sector [3]. - The firm noted that pricing pressures in the sector are easing and leverage levels are declining, suggesting a transition phase with "plenty of opportunity" for growth [4].

Group 1 - Sweetgreen, Inc. is experiencing decent revenue growth but struggles to achieve profitability, which raises concerns about its future performance [1][2] - The company operates fast-casual restaurants focusing on healthy food and beverages, and offers online and mobile ordering [2] - The current market environment for experiential businesses has been challenging, with recent disappointing earnings reported by previously successful companies in this sector [2] Group 2 - There is a belief that certain AI stocks present greater upside potential and lower downside risk compared to Sweetgreen [3]

Core Viewpoint - Sunrun Inc. (NASDAQ:RUN) is experiencing a decline in share price despite recent positive developments, including a joint venture aimed at financing distributed energy assets. Group 1: Share Price Movement - The share price of Sunrun Inc. fell by 5.65% between December 31, 2025, and January 7, 2026, making it one of the Energy Stocks that Lost the Most This Week [1] - Deutsche Bank lowered its price target on Sunrun from $20 to $19 while maintaining a 'Hold' rating on the shares [2] Group 2: Joint Venture and Financing - Sunrun announced a joint venture with HA Sustainable Infrastructure to finance distributed energy assets across the U.S., with HASI investing $500 million over 18 months to finance 300 MW of solar and energy storage capacity [3] - The joint venture allows Sunrun to retain a significant long-term ownership stake in the assets while providing greater flexibility in arranging senior project debt [3] - CFO Danny Abajian highlighted that this innovative financing structure is a first-of-a-kind for residential storage and solar financing, aiming for an efficient capital structure that could yield better proceeds than traditional financing arrangements [4] Group 3: Performance and Market Position - Sunrun achieved gains of almost 99% in the previous year, ranking among the 11 Best Performing Energy Stocks in 2025 [5] - Despite its strong performance, there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [5]

Core Viewpoint - First Solar, Inc. (NASDAQ:FSLR) is experiencing mixed analyst sentiments, with Jefferies downgrading the stock while Deutsche Bank raises its price target, indicating a divergence in market outlook for the company. Group 1: Stock Performance - The share price of First Solar fell by 7.7% between December 31, 2025, and January 7, 2026, making it one of the Energy Stocks that Lost the Most This Week [1]. Group 2: Analyst Ratings and Price Targets - Jefferies downgraded First Solar from 'Buy' to 'Hold' and reduced its price target from $269 to $260, citing concerns over the company's bookings and management's previous guidance cuts [3]. - Deutsche Bank raised its price target on First Solar from $255 to $300 while maintaining a 'Buy' rating, reflecting a more optimistic outlook compared to Jefferies [4]. Group 3: Market Concerns - Jefferies expressed caution for First Solar in 2026, highlighting expectations that the company will not improve its bookings and that recent price declines in Germany could underwhelm investor expectations [3].